L. Bortot, C. Corvaja, V. Fanotto, F. Puglisi
Vol.3 (2018), issue 2, pag.1-10

Received 24/03/2018
Accepted for pubblication 22/04/2018
Published May 2018
Review by Single-blind
jQuery UI Dialog - Animation

Although breast cancer is generally considered to be indolent in the elderly, there is certain variability in its characteristics and clinical outcomes in the oldest population. Indeed, a substantial proportion of older women have a diagnosis of triple-negative breast cancer (TNBC), a subtype with usually poor prognosis. TNBC in the elderly represents a substantial treatment challenge: geriatric assessment and life expectancy evaluation are mandatory. Local treatments, such as surgery and radiation, and adjuvant chemotherapy play a central role in early stage TNBC whereas chemotherapy remains the cornerstone of the systemic treatment of metastatic TNBC. However, few randomized controlled trials have been conducted to evaluate the e ectiveness of breast cancer treatments on women aged 70 or older. Hence, the less aggressive treatment strategies, usually chosen to respect pa- tients’ frailty and vulnerability, are mostly empirical and not evidence-based. As a consequence, the impact of potential undertreatment on cancer recur- rence and overall survival is not known. e identi cation of new strategies is therefore urgently needed to guarantee the best therapeutic chances to elderly patients with TNBC without exposing them to unacceptable and dangerous toxicities.